The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Infectious Diseases-Global Market Insights and Sales Trends 2024
Synopsis
When infection attacks the body, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic; including antitubercular), antiviral, antifungal and antiparasitic (including antiprotozoal and antihelminthic) agents.
The global Infectious Diseases market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Infectious Diseases in various end use industries. The expanding demands from the Hospitals/Clinical Laboratories, Reference Laboratories, Academic/Research Institutes and Other, are propelling Infectious Diseases market. Antibacterial Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antiviral Drugs segment is estimated at % CAGR for the next seven-year period.
Depending on the severity and the type of infection, the antibiotic may be given by mouth or by injection, or may be applied topically. Severe infections of the brain are usually treated with intravenous antibiotics. Sometimes, multiple antibiotics are used in case there is resistance to one antibiotic.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Infectious Diseases, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Infectious Diseases market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Infectious Diseases market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Infectious Diseases sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Infectious Diseases covered in this report include F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Astellas Pharma and AstraZeneca, etc.
The global Infectious Diseases market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Astellas Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Chimerix Pharmaceuticals
Cubist
Eli Lilly
Isis Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Sanofi
Vertex
Global Infectious Diseases market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Infectious Diseases market, Segment by Type:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasitic Drugs
Global Infectious Diseases market, by Application
Hospitals/Clinical Laboratories
Reference Laboratories
Academic/Research Institutes
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Infectious Diseases companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
When infection attacks the body, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic; including antitubercular), antiviral, antifungal and antiparasitic (including antiprotozoal and antihelminthic) agents.
The global Infectious Diseases market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Infectious Diseases in various end use industries. The expanding demands from the Hospitals/Clinical Laboratories, Reference Laboratories, Academic/Research Institutes and Other, are propelling Infectious Diseases market. Antibacterial Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antiviral Drugs segment is estimated at % CAGR for the next seven-year period.
Depending on the severity and the type of infection, the antibiotic may be given by mouth or by injection, or may be applied topically. Severe infections of the brain are usually treated with intravenous antibiotics. Sometimes, multiple antibiotics are used in case there is resistance to one antibiotic.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Infectious Diseases, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Infectious Diseases market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Infectious Diseases market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Infectious Diseases sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Infectious Diseases covered in this report include F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Astellas Pharma and AstraZeneca, etc.
The global Infectious Diseases market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Astellas Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Chimerix Pharmaceuticals
Cubist
Eli Lilly
Isis Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Sanofi
Vertex
Global Infectious Diseases market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Infectious Diseases market, Segment by Type:
Antibacterial Drugs
Antiviral Drugs
Antifungal Drugs
Antiparasitic Drugs
Global Infectious Diseases market, by Application
Hospitals/Clinical Laboratories
Reference Laboratories
Academic/Research Institutes
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Infectious Diseases companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Infectious Diseases
1.1 Infectious Diseases Market Overview
1.1.1 Infectious Diseases Product Scope
1.1.2 Infectious Diseases Market Status and Outlook
1.2 Global Infectious Diseases Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Infectious Diseases Market Size by Region (2018-2029)
1.4 Global Infectious Diseases Historic Market Size by Region (2018-2023)
1.5 Global Infectious Diseases Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Infectious Diseases Market Size (2018-2029)
1.6.1 North America Infectious Diseases Market Size (2018-2029)
1.6.2 Europe Infectious Diseases Market Size (2018-2029)
1.6.3 Asia-Pacific Infectious Diseases Market Size (2018-2029)
1.6.4 Latin America Infectious Diseases Market Size (2018-2029)
1.6.5 Middle East & Africa Infectious Diseases Market Size (2018-2029)
2 Infectious Diseases Market by Type
2.1 Introduction
2.1.1 Antibacterial Drugs
2.1.2 Antiviral Drugs
2.1.3 Antifungal Drugs
2.1.4 Antiparasitic Drugs
2.2 Global Infectious Diseases Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Infectious Diseases Historic Market Size by Type (2018-2023)
2.2.2 Global Infectious Diseases Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Infectious Diseases Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Infectious Diseases Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Infectious Diseases Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Infectious Diseases Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Infectious Diseases Revenue Breakdown by Type (2018-2029)
3 Infectious Diseases Market Overview by Application
3.1 Introduction
3.1.1 Hospitals/Clinical Laboratories
3.1.2 Reference Laboratories
3.1.3 Academic/Research Institutes
3.1.4 Other
3.2 Global Infectious Diseases Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Infectious Diseases Historic Market Size by Application (2018-2023)
3.2.2 Global Infectious Diseases Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Infectious Diseases Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Infectious Diseases Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Infectious Diseases Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Infectious Diseases Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Infectious Diseases Revenue Breakdown by Application (2018-2029)
4 Infectious Diseases Competition Analysis by Players
4.1 Global Infectious Diseases Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Infectious Diseases as of 2022)
4.3 Date of Key Players Enter into Infectious Diseases Market
4.4 Global Top Players Infectious Diseases Headquarters and Area Served
4.5 Key Players Infectious Diseases Product Solution and Service
4.6 Competitive Status
4.6.1 Infectious Diseases Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 F. Hoffmann-La Roche
5.1.1 F. Hoffmann-La Roche Profile
5.1.2 F. Hoffmann-La Roche Main Business
5.1.3 F. Hoffmann-La Roche Infectious Diseases Products, Services and Solutions
5.1.4 F. Hoffmann-La Roche Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.1.5 F. Hoffmann-La Roche Recent Developments
5.2 Gilead Sciences
5.2.1 Gilead Sciences Profile
5.2.2 Gilead Sciences Main Business
5.2.3 Gilead Sciences Infectious Diseases Products, Services and Solutions
5.2.4 Gilead Sciences Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Sciences Recent Developments
5.3 GlaxoSmithKline
5.3.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline Infectious Diseases Products, Services and Solutions
5.3.4 GlaxoSmithKline Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Infectious Diseases Products, Services and Solutions
5.4.4 Johnson & Johnson Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Infectious Diseases Products, Services and Solutions
5.5.4 Merck Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Infectious Diseases Products, Services and Solutions
5.6.4 Pfizer Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 AbbVie
5.7.1 AbbVie Profile
5.7.2 AbbVie Main Business
5.7.3 AbbVie Infectious Diseases Products, Services and Solutions
5.7.4 AbbVie Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.7.5 AbbVie Recent Developments
5.8 Astellas Pharma
5.8.1 Astellas Pharma Profile
5.8.2 Astellas Pharma Main Business
5.8.3 Astellas Pharma Infectious Diseases Products, Services and Solutions
5.8.4 Astellas Pharma Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.8.5 Astellas Pharma Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Infectious Diseases Products, Services and Solutions
5.9.4 AstraZeneca Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
5.10 Bayer
5.10.1 Bayer Profile
5.10.2 Bayer Main Business
5.10.3 Bayer Infectious Diseases Products, Services and Solutions
5.10.4 Bayer Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.10.5 Bayer Recent Developments
5.11 Bristol-Myers Squibb
5.11.1 Bristol-Myers Squibb Profile
5.11.2 Bristol-Myers Squibb Main Business
5.11.3 Bristol-Myers Squibb Infectious Diseases Products, Services and Solutions
5.11.4 Bristol-Myers Squibb Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.11.5 Bristol-Myers Squibb Recent Developments
5.12 Chimerix Pharmaceuticals
5.12.1 Chimerix Pharmaceuticals Profile
5.12.2 Chimerix Pharmaceuticals Main Business
5.12.3 Chimerix Pharmaceuticals Infectious Diseases Products, Services and Solutions
5.12.4 Chimerix Pharmaceuticals Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.12.5 Chimerix Pharmaceuticals Recent Developments
5.13 Cubist
5.13.1 Cubist Profile
5.13.2 Cubist Main Business
5.13.3 Cubist Infectious Diseases Products, Services and Solutions
5.13.4 Cubist Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.13.5 Cubist Recent Developments
5.14 Eli Lilly
5.14.1 Eli Lilly Profile
5.14.2 Eli Lilly Main Business
5.14.3 Eli Lilly Infectious Diseases Products, Services and Solutions
5.14.4 Eli Lilly Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.14.5 Eli Lilly Recent Developments
5.15 Isis Pharmaceuticals
5.15.1 Isis Pharmaceuticals Profile
5.15.2 Isis Pharmaceuticals Main Business
5.15.3 Isis Pharmaceuticals Infectious Diseases Products, Services and Solutions
5.15.4 Isis Pharmaceuticals Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.15.5 Isis Pharmaceuticals Recent Developments
5.16 Mitsubishi Tanabe Pharma
5.16.1 Mitsubishi Tanabe Pharma Profile
5.16.2 Mitsubishi Tanabe Pharma Main Business
5.16.3 Mitsubishi Tanabe Pharma Infectious Diseases Products, Services and Solutions
5.16.4 Mitsubishi Tanabe Pharma Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.16.5 Mitsubishi Tanabe Pharma Recent Developments
5.17 Novartis
5.17.1 Novartis Profile
5.17.2 Novartis Main Business
5.17.3 Novartis Infectious Diseases Products, Services and Solutions
5.17.4 Novartis Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.17.5 Novartis Recent Developments
5.18 Sanofi
5.18.1 Sanofi Profile
5.18.2 Sanofi Main Business
5.18.3 Sanofi Infectious Diseases Products, Services and Solutions
5.18.4 Sanofi Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.18.5 Sanofi Recent Developments
5.19 Vertex
5.19.1 Vertex Profile
5.19.2 Vertex Main Business
5.19.3 Vertex Infectious Diseases Products, Services and Solutions
5.19.4 Vertex Infectious Diseases Revenue (US$ Million) & (2018-2023)
5.19.5 Vertex Recent Developments
6 North America
6.1 North America Infectious Diseases Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Infectious Diseases Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Infectious Diseases Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Infectious Diseases Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Infectious Diseases Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Infectious Diseases Market Dynamics
11.1 Infectious Diseases Industry Trends
11.2 Infectious Diseases Market Drivers
11.3 Infectious Diseases Market Challenges
11.4 Infectious Diseases Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
